Please login to the form below

Not currently logged in
Email:
Password:

propofol

This page shows the latest propofol news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca sells rights to seven anaesthetics in $770m deal

AstraZeneca sells rights to seven anaesthetics in $770m deal

topical anaesthetics Diprivan (propofol) and EMLA (lidocain and prilocaine), plus five local anaesthetics.

Latest news

  • R&D news in brief

    SkyePharma and Endo halt Propofol IDD-DTM development. SkyePharma says it has agreed with US partner Endo to terminate joint development of Propofol IDD-DTM, an injectable anaesthetic and sedative that ... Under the terms of the December 2002 agreement,

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and Diprivan (propofol), a short acting intravenous sedative/ anaesthetic.

  • Pharma deals in February 2015 Pharma deals in February 2015

    The sedative and analgesic propofol recall on the very day the acquisition was announced due, and not for the first time, to particulate iron embedded in the neck of a vial

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics